CRISPR Therapeutics AG

CRSP Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Ownership

Chart provided by TradingView

Income
Balance Sheet
Cash Flow
CRSP Income Statement
CRSP Balance Sheet
CRSP Cash Flow
Congress Trading

Recent trades of CRSP by members of U.S. Congress

Politician Type Traded
Thomas R. Suozzi House / D Sale $50,001 - $100,000 Sep. 20, 2021
Thomas R. Suozzi House / D Purchase $50,001 - $100,000 Jun. 03, 2021
Marjorie Taylor Greene House / R Purchase $1,001 - $15,000 Jan. 21, 2021
James M. Inhofe Senate / R Sale (Partial) $1,001 - $15,000 Jan. 05, 2021
James M. Inhofe Senate / R Sale (Partial) $50,001 - $100,000 Dec. 22, 2020
James M. Inhofe Senate / R Sale (Partial) $15,001 - $50,000 Jun. 19, 2018
James M. Inhofe Senate / R Purchase $15,001 - $50,000 Oct. 19, 2017
CRSP Stock Insider Trading Activity
Name
Type
Shares
Price
Shares Held
Date
Reported
CRSP Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CRSP Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by CRSP's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
Corporate Lobbying

Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) Oct. 22, 2024
  • Patent Title: Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions Jul. 16, 2024
  • Patent Title: Gene editing for hemophilia a with improved factor viii expression Jun. 25, 2024
  • Patent Title: Compositions and methods for the depletion of cd117+ cells Apr. 16, 2024
  • Patent Title: Masked chimeric antigen receptor specific to tyrosine-protein kinase like 7 (ptk7) and immune cells expressing such Mar. 12, 2024
  • Patent Title: Compositions and methods for gene editing Mar. 05, 2024
  • Patent Title: Materials and methods for treatment of glycogen storage disease type 1a Jan. 09, 2024
  • Patent Title: Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence Jan. 02, 2024
  • Patent Title: Materials and methods for treatment of alpha-1 antitrypsin deficiency Dec. 26, 2023
  • Patent Title: Methods and compositions for efficient gene deletion Dec. 05, 2023
  • Patent Title: Compositions and methods for genomic editing by insertion of donor polynucleotides Nov. 28, 2023
  • Patent Title: Anti-idiotype antibodies targeting anti-cd70 chimeric antigen receptor Oct. 24, 2023
  • Patent Title: Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence Jun. 20, 2023
  • Patent Title: Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence Jun. 20, 2023
  • Patent Title: Methods and compositions for treating cancer May. 16, 2023
  • Patent Title: Materials and methods for engineering cells and uses thereof in immuno-oncology Apr. 11, 2023
  • Patent Title: Gene-edited natural killer cells Feb. 28, 2023
  • Patent Title: Universal donor cells Feb. 14, 2023
  • Patent Title: Universal donor cells Jan. 31, 2023
  • Patent Title: Materials and methods for treatment of friedreich ataxia and other related disorders Jan. 31, 2023
  • Patent Title: Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders Jan. 24, 2023
  • Patent Title: Gene editing for hemophilia a with improved factor viii expression Dec. 20, 2022
  • Patent Title: Genetically engineered t cells with regnase-1 and/or tgfbrii disruption have improved functionality and persistence Nov. 15, 2022
  • Patent Title: Compositions and methods for differentiating stem cells into nk cells Oct. 18, 2022
  • Patent Title: Materials and methods for engineering cells and uses thereof in immuno-oncology Oct. 18, 2022
  • Patent Title: Gene-edited natural killer cells Oct. 04, 2022
  • Patent Title: Universal donor cells Sep. 06, 2022
  • Patent Title: Universal donor cells Sep. 06, 2022
  • Patent Title: Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders Aug. 09, 2022
  • Patent Title: Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 Jul. 19, 2022
  • Patent Title: Compositions and methods for genomic editing by insertion of donor polynucleotides May. 17, 2022
  • Patent Title: Materials and methods for engineering cells and uses thereof in immuno-oncology Apr. 12, 2022
  • Patent Title: Methods and compositions for treating cancer Feb. 22, 2022
  • Patent Title: Materials and methods for engineering cells and uses thereof in immuno-oncology Dec. 28, 2021
  • Patent Title: Materials and methods for engineering cells and uses thereof in immuno-oncology Dec. 21, 2021
  • Patent Title: Materials and methods for engineering cells and uses thereof in immuno-oncology Dec. 07, 2021
  • Patent Title: Universal donor cells Nov. 23, 2021
  • Patent Title: Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders Nov. 16, 2021
  • Patent Title: Materials and methods for engineering cells and uses thereof in immuno-oncology Nov. 09, 2021
  • Patent Title: Materials and methods for engineering cells and uses thereof in immuno-oncology Oct. 05, 2021
  • Patent Title: Universal donor cells Sep. 14, 2021
  • Patent Title: Universal donor cells Sep. 14, 2021
  • Patent Title: Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) Sep. 14, 2021
  • Patent Title: Universal donor cells Sep. 14, 2021
  • Patent Title: Universal donor cells Sep. 14, 2021
  • Patent Title: Universal donor cells Aug. 31, 2021
  • Patent Title: Materials and methods for treatment of hereditary haemochromatosis Aug. 10, 2021
  • Patent Title: Materials and methods for engineering cells and uses thereof in immuno-oncology Jul. 27, 2021
  • Patent Title: Materials and methods for engineering cells and uses thereof in immuno-oncology May. 25, 2021
  • Patent Title: Universal donor cells May. 18, 2021
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of CRSP in WallStreetBets Daily Discussion

CRSP News

Recent insights relating to CRSP

CNBC Recommendations

Recent picks made for CRSP stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CRSP

CRSP Top Shareholders
Shareholder
Shares Held
CRSP Options Owners
Shareholder
Security
Underlying Shares

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CRSP Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CRSP Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
Back To Top